Business
Steriwave Up for 2025 “Product of the Year” Award
Ondine Biomedical Inc. has announced that its Steriwave® nasal photodisinfection technology has been selected as a finalist for the 2025 Bionow Product of the Year Award, a significant recognition given a 50% increase in nominations this year. This non-antibiotic antimicrobial process, which eliminates nasal pathogens to prevent surgical site infections, has seen growing adoption in the UK healthcare landscape, with clinical partnerships at Mid Yorkshire Teaching NHS Trust and NHS Guy's and St. Thomas's demonstrating significant reductions in antibiotic use and improved patient outcomes. The nomination highlights Steriwave's potential to become a standard of care, reducing healthcare costs and recovery times. Disclaimer*
About this update from Ondine Biomedical, Inc.
[{"type":"text","content":"\n\n2 February 2026 \nONDINE BIOMEDICAL INC.\n(\"Ondine Biomedical\", \"Ondine\" or the \"Company\")\n\nSteriwave Up for 2025 \"Product of the Year\" Award\nOndine's Steriwave® Shortlisted as Finalist for Prestigious 2025 Bionow Product of the Year Award\nOndine Biomedical Inc. (AIM: OBI) is proud to announce that its pioneering nasal photodisinfection technology, Steriwave®, has been shortlisted as a finalist for the Product of the Year Award at the 2025 Bionow Awards.\nThe Bionow Awards are a landmark event in the life sciences calendar, recognizing excellence, innovation, and world-class impact. This year's award process was record-breaking, with a 50% increase in nominations, making the shortlisting of Steriwave a significant testament to its clinical and commercial momentum within the UK healthcare landscape.\nSteriwave uses a patented light-activated antimicrobial process to eliminate pathogens in the nose-a primary reservoir for bacteria that cause surgical site infections (SSIs). This non-antibiotic approach is critical in the global effort toward better antimicrobial stewardship.\nOndine's journey to this shortlisting has been bolstered by key clinical partnerships in the UK. The company is exceptionally pleased to acknowledge the early and steadfast support of the Innovation Team at Mid Yorkshire Teaching NHS Trust, led by Dr. Stuart Bond, and the clinical team led by Dr. Simon Jones, the first to adopt Steriwave into clinical practice in the UK, and the early clinical work of NHS Guy's and St. Thomas's ENT team led by Professor Claire Hopkins, whose studies with Steriwave demonstrated better outcomes for ENT patients including significant reductions in antibiotic use. These teams were instrumental in recognizing and proving the clear benefits of this non-antibiotic approach to infection control and patient safety as well as addressing antibiotic stewardship.\nCarolyn Cross, CEO of Ondine Biomedical, commented:\n\"With so many hospitals confirming significant results, including SSI and mortality rate reductions and cost savings, we are grateful for the recognition to shine more light on the big impact photodisinfection-pioneered by Emeritus Professor Michael Wilson of University College London-h...